NCT00081276: 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer |
|
|
| Completed | 2 | 48 | US | triapine, 3-AP, OCX-191, cisplatin, CACP, CDDP, CPDD, DDP, laboratory biomarker analysis | National Cancer Institute (NCI) | Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer | 01/07 | | | |
NCT00941070: Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer |
|
|
| Completed | 2 | 26 | US | triapine, 3-AP, OCX-191, cisplatin, CACP, CDDP, CPDD, DDP, external beam radiation therapy, EBRT, quality-of-life assessment, quality of life assessment, questionnaire administration, fludeoxyglucose F 18, 18FDG, FDG, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed, computed tomography, tomography, computed | National Cancer Institute (NCI) | Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Therapy-related Toxicity | 04/12 | 07/12 | | |
